{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-001579","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2022-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.114350+00:00","generated_at":"2026-06-27T05:50:29.849019+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tactile Medical Q4 rev $61.7M (+4% YoY); net loss $7.5M; FY 2022 guidance $235-240M","bullets":["Q4 revenue $61.7M (+4% YoY); full year 2021 revenue $208.1M (+11% YoY).","Q4 net loss $7.5M ($0.38 loss per share) vs net income $12.1M ($0.61 EPS) in Q4 2020.","Adjusted EBITDA Q4 $9.5M vs $10.8M prior year; full year $17.7M vs $16.0M.","FY 2022 revenue guidance $235-240M (13-15% growth) with Omicron and staffing headwinds expected in H1.","Qui tam lawsuit dismissed with no damages; board appointed Valerie Asbury and D. Brent Shafer in Jan 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-001579","json":"https://secwatch.observer/filing/0001558370-22-001579.json","markdown":"https://secwatch.observer/filing/0001558370-22-001579.md","text":"https://secwatch.observer/filing/0001558370-22-001579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000155837022001579/0001558370-22-001579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000155837022001579/tcmd-20220222x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:50:29.849019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}